85 related articles for article (PubMed ID: 8039940)
1. Biocompatibility of cardiopulmonary bypass: influence on blood compatibility of device type, mode of blood flow and duration of application.
Sundaram S; Courtney JM; Taggart DP; Tweddel AC; Martin W; McQuiston AM; Wheatley DJ; Lowe GD
Int J Artif Organs; 1994 Feb; 17(2):118-28. PubMed ID: 8039940
[TBL] [Abstract][Full Text] [Related]
2. Patterns of blood response during cardiopulmonary bypass.
Sundaram S; Irvine L; Courtney JM; Taggart DP; Wheatley DJ; Lowe GD
Int J Artif Organs; 1992 Apr; 15(4):243-8. PubMed ID: 1587648
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of factor XII activity and granulocyte elastase release during cardiopulmonary bypass.
Irvine L; Sundaram S; Courtney JM; Taggart DP; Wheatley DJ; Lowe GD
ASAIO Trans; 1991; 37(4):569-71. PubMed ID: 1768490
[TBL] [Abstract][Full Text] [Related]
4. Endotoxemia, complement, and white blood cell activation in cardiac surgery: a randomized trial of laxatives and pulsatile perfusion.
Taggart DP; Sundaram S; McCartney C; Bowman A; McIntyre H; Courtney JM; Wheatley DJ
Ann Thorac Surg; 1994 Feb; 57(2):376-82. PubMed ID: 8311599
[TBL] [Abstract][Full Text] [Related]
5. Respiratory dysfunction and white cell activation following cardiopulmonary bypass: comparison of membrane and bubble oxygenators.
Martin W; Carter R; Tweddel A; Belch J; el-Fiky M; McQuiston AM; McLaren M; Wheatley DJ
Eur J Cardiothorac Surg; 1996; 10(9):774-83. PubMed ID: 8905281
[TBL] [Abstract][Full Text] [Related]
6. Effects of pulsatile and nonpulsatile perfusion mode during extracorporeal circulation--a comparative clinical study.
Dapper F; Neppl H; Wozniak G; Strube I; Zickmann B; Hehrlein FW; Neuhof H
Thorac Cardiovasc Surg; 1992 Dec; 40(6):345-51. PubMed ID: 1290181
[TBL] [Abstract][Full Text] [Related]
7. [Use of cardiopulmonary bypass decreases leukocyte count and activation of the complement system].
Bochenek A; Religa Z; Kokot F; Knapik P; Wnuk R; Komarski K; Wojnar J; Pietrzycki A; Skiba J
Kardiol Pol; 1992; 36(2):67-72. PubMed ID: 1583828
[TBL] [Abstract][Full Text] [Related]
8. Biocompatibility of leukocyte removal filters during leukocyte filtration of cardiopulmonary bypass perfusate.
Gu YJ; Obster R; Haan J; Gallandat Huet RC; Eijgelaar A; van Oeveren W
Artif Organs; 1993 Jul; 17(7):660-5. PubMed ID: 8338443
[TBL] [Abstract][Full Text] [Related]
9. Biocompatibility of poly2methoxyethylacrylate coating for cardiopulmonary bypass.
Noguchi M; Eishi K; Tada S; Yamachika S; Hazama S; Izumi K; Tanigawa K
Ann Thorac Cardiovasc Surg; 2003 Feb; 9(1):22-8. PubMed ID: 12667126
[TBL] [Abstract][Full Text] [Related]
10. Complement, leukocytes, and leukocyte elastase in full-term neonates undergoing cardiac operation.
Seghaye MC; Duchateau J; Grabitz RG; Nitsch G; Marcus C; Messmer BJ; von Bernuth G
J Thorac Cardiovasc Surg; 1994 Jul; 108(1):29-36. PubMed ID: 8028376
[TBL] [Abstract][Full Text] [Related]
11. Biocompatibility of extracorporeal circulation with autooxygenation.
Bochenek A; Religa Z; Kokot F; Wnuk-Wojnar AM; Wojnar J; Wnuk R; Gallert G; Skiba J
Eur J Cardiothorac Surg; 1992; 6(8):397-402. PubMed ID: 1389244
[TBL] [Abstract][Full Text] [Related]
12. Blood activation during neonatal extracorporeal life support.
Plötz FB; van Oeveren W; Bartlett RH; Wildevuur CR
J Thorac Cardiovasc Surg; 1993 May; 105(5):823-32. PubMed ID: 7683735
[TBL] [Abstract][Full Text] [Related]
13. Blood compatibility of two different types of membrane oxygenator during cardiopulmonary bypass in infants.
Gu YJ; Boonstra PW; Akkerman C; Mungroop H; Tigchelaar I; Van Oeveren W
Int J Artif Organs; 1994 Oct; 17(10):543-8. PubMed ID: 7896428
[TBL] [Abstract][Full Text] [Related]
14. Complement and leukocytes during cardiopulmonary bypass: effects on plasma C3d and C5a, leukocyte count, release of granulocyte elastase and granulocyte chemotaxis.
Knudsen F; Pedersen JO; Juhl O; Nielsen AH; Jersild C
J Cardiothorac Anesth; 1988 Apr; 2(2):164-70. PubMed ID: 17171907
[TBL] [Abstract][Full Text] [Related]
15. Biocompatibility of a heparin-bonded membrane oxygenator (Carmeda MAXIMA) during the first 90 minutes of cardiopulmonary bypass: clinical comparison with the conventional system.
Shigemitsu O; Hadama T; Takasaki H; Mori Y; Kimura T; Miyamoto S; Sako H; Soeda T; Kawawaki Y; Uchida Y
Artif Organs; 1994 Dec; 18(12):936-41. PubMed ID: 7887832
[TBL] [Abstract][Full Text] [Related]
16. Renal vein fibrin degradation products (FDP's) in glomerulonephritis.
Tomura S; Ideura T; Ida T; Osaka Y; Kuriyama R; Abe T; Takeuchi J
Clin Nephrol; 1979 Dec; 12(6):248-53. PubMed ID: 527278
[TBL] [Abstract][Full Text] [Related]
17. Systemic leukocyte filtration during cardiopulmonary bypass.
Fabbri A; Manfredi J; Piccin C; Soffiati G; Carta MR; Gasparotto E; Nardon G
Perfusion; 2001 Mar; 16 Suppl():11-8. PubMed ID: 11334202
[TBL] [Abstract][Full Text] [Related]
18. Influence of 4 different membrane oxygenators on inflammation-like processes during extracorporeal circulation with pulsatile and non-pulsatile flow.
Dapper F; Neppl H; Wozniak G; Strube I; Boldt J; Hehrlein FW; Neuhof H
Eur J Cardiothorac Surg; 1992; 6(1):18-24. PubMed ID: 1371929
[TBL] [Abstract][Full Text] [Related]
19. Complement activation during cardiopulmonary bypass. Comparison of bubble and membrane oxygenators.
Cavarocchi NC; Pluth JR; Schaff HV; Orszulak TA; Homburger HA; Solis E; Kaye MP; Clancy MS; Kolff J; Deeb GM
J Thorac Cardiovasc Surg; 1986 Feb; 91(2):252-8. PubMed ID: 3511328
[TBL] [Abstract][Full Text] [Related]
20. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass.
Blauhut B; Gross C; Necek S; Doran JE; Späth P; Lundsgaard-Hansen P
J Thorac Cardiovasc Surg; 1991 Jun; 101(6):958-67. PubMed ID: 1710008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
